Gilead’s Trodelvy approved by FDA for metastatic breast cancer
06 Feb 2023
Clinical ResultDrug ApprovalPhase 3Accelerated Approval
Preview
Source: PMLiVE
Gilead Science’s Trodelvy (sacituzumab govitecan-hziy) has been approved by the US Food and Administration (FDA) to treat metastatic breast cancer, the company announced.
The authorisation is specifically for adult patients with unresectable locally advanced or metastatic HR-positive, HER2-negative (HR+/HER2-) breast cancerHER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
HR+/HER2- breast cancerHR+/HER2- breast cancer is the most common type of breast cancer, accounting for around 70% of all new cases, or nearly 400,000 diagnoses worldwide each year.
Almost one in three cases of early-stage breast cancer eventually become metastatic, and among patients with HR+/HER2- metastatic diseaseHR+/HER2- metastatic disease, the five-year relative survival rate is 30%.
As patients with HR+/HER2- metastatic breast cancerHR+/HER2- metastatic breast cancer become resistant to endocrine-based therapy, their primary treatment option is limited to single-agent chemotherapy.
In the study, Trodelvy showed a 34% reduction in risk of disease progression or death, as well as an OS benefit of 3.2 months over single-agent chemotherapy.
Trodelvy also significantly improved additional secondary endpoint measures, including objective response rate and time to deterioration.
“The FDA approval is an important step forward for both women and men living with metastatic breast cancer, especially for those individuals whose tumour is no longer responding to endocrine-based therapies and who are facing a poor prognosis,” said Laura Carfang, executive director at SurvivingBreastCancer.org.
Trodelvy is already approved in more than 40 countries to treat adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
“We are pleased that Trodelvy could now provide new hope for people living with pre-treated HR+/HER2- metastatic breast cancerHR+/HER2- metastatic breast cancer, building on the transformative role that Trodelvy is already playing for people with metastatic triple-negative breast cancer,” said Daniel O'Day, chairman and chief executive officer at Gilead.
Trodelvy is also approved in the US under the accelerated approval pathway for pretreated adult patients with locally advanced or metastatic urothelial cancer.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.